FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
<< Prev  11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 Next >>
 
TXT Petition Seeks Removal of Bamboo’s NarxCare Software
04/28/2023
 
 
TXT Gene Therapy Guide on NonClinical Biodistribution
04/28/2023
 
 
TXT Teva Recalls Fentanyl Lots Over Product Insert
04/28/2023
 
 
TXT FDA Approves Otsuka/Lundbeck Schizophrenia Drug
04/28/2023
 
 
TXT ViiV Dovato Ad Claims Challenged
04/27/2023
 
 
TXT Drug Supply Chain Independence Bill
04/27/2023
 
 
TXT Ultromics Gets Breakthrough Status for AI Device
04/27/2023
 
 
TXT FDA Approves Oral Fecal Microbiota Capsules
04/27/2023
 
 
TXT Prevent Makena Compounding: Public Citizen
04/27/2023
 
 
TXT Gillibrand Bill to Speed FDA Approval of Some Drugs
04/27/2023
 
 
TXT Quality Management Maturity Dividing Industry: PDA
04/27/2023
 
 
TXT FDA Planning TV Ad Endorser Research
04/27/2023
 
 
TXT Lilly Planning Tirzepatide Submission Soon
04/27/2023
 
 
TXT FDA Lifts Warning Letter Against Medtronic
04/26/2023
 
 
TXT CVM Electronic Submission Registration
04/26/2023
 
 
TXT DefenCath NDA to be Resubmitted by Mid-May
04/26/2023
 
 
TXT Nonrandom Data Can Emulate Random Trials: Study
04/26/2023
 
 
TXT Iptacopan FDA Submission Coming Soon: Novartis
04/26/2023
 
 
TXT Alvotech FDA-483 Released
04/26/2023
 
 
TXT Bankrupt Akorn Recalls All Products
04/26/2023
 
 
TXT Vertex Gains Expanded Use for Cystic Fibrosis Drug
04/26/2023
 
 
TXT Advisors Asked About Olaparib sNDA Population
04/26/2023
 
 
TXT CGMP Violations at Egypt’s Pharmaplast
04/25/2023
 
 
TXT Florida Files 2nd Drug Import Suit Against FDA
04/25/2023
 
 
TXT QS, MDR, Other Violations in Medivance Inspection
04/25/2023
 
 
TXT Medolife Illegally Selling Unapproved New Drugs: FDA
04/25/2023
 
 
TXT Streamlined Cancer Trials Can Cause ‘Discomfort’: Singh
04/25/2023
 
 
TXT Biogen Accelerated Approval for ALS Drug
04/25/2023
 
 
TXT Senate Bipartisan Agreement on FDA Reform Bills
04/25/2023
 
 
TXT FDA Sends ‘Non-Compliance’ Letter to Sun Pharma
04/25/2023
 
 
TXT Medtronic’s MiniMed 780G Gets FDA Approval
04/24/2023
 
 
TXT Generic Group Questions Guide on Guidance Meetings
04/24/2023
 
 
TXT Foghorn Therapeutics Hit with Partial Clinical Hold
04/24/2023
 
 
TXT Supreme Court Gives FDA Temporary Victory
04/24/2023
 
 
TXT OPDP Plans Survey on DTC Quantitative Claims
04/24/2023
 
 
TXT Avanos Medical Recalls Respiratory Suction Device
04/21/2023
 
 
TXT FDA Extends Review of Daiichi Leukemia NDA
04/21/2023
 
 
TXT CDER Denies Bausch Petition on Duobrii ANDAs
04/21/2023
 
 
TXT Novartis Gets Another Facility OK’d for Pluvicto
04/21/2023
 
 
TXT DTC Research Raises Concern on Endpoints in Cancer Ads
04/21/2023
 
 
TXT 10 Observations in Lupin FDA-483
04/20/2023
 
 
TXT Sarepta Comments on Golodirsen PSG
04/20/2023
 
 
TXT GE Healthcare’s Carescape Patient Monitor Cleared
04/20/2023
 
 
TXT FDA Describes New QSAR Model
04/20/2023
 
 
TXT FDA Failed to Collect $45 bil. Drug Trial Fines: Students
04/20/2023
 
 
TXT Califf Testifies on Accelerated Approvals
04/20/2023
 
 
TXT BelGene Gastric Cancer Drug Trial Hits Primary Endpoint
04/20/2023
 
 
TXT CGMP Violations at Zermat International
04/19/2023
 
 
TXT Fresenius Kabi Recalls Ivenix Infusion Device
04/19/2023
 
 
TXT North American Diagnostics Illegal Covid Tests
04/19/2023
 
 
TXT Radiation Syndrome Drug Development Guidance
04/19/2023
 
 
TXT NCI Sees Revumenib Promise for Some Leukemias
04/19/2023
 
 
TXT FDA Cautions Compounders on Bulk Sources
04/19/2023
 
 
TXT FDA Drug Inspections Slow to Recover: Analysis
04/19/2023
 
 
TXT Guidance Shows Importance of Sponsor Oversight: Attorneys
04/19/2023
 
 
TXT Generic Mifepristone Maker Sues FDA
04/19/2023
 
 
TXT High Court Adds 2 Days to Mifepristone Stay
04/19/2023
 
 
TXT EMA/FDA Bioequivalence Info Sharing Pact Adds Ireland
04/19/2023
 
 
TXT FDA OKs 2nd Covid Booster for Some People
04/18/2023
 
 
TXT Lessons Learned from Rare Disease Trials During Covid
04/18/2023
 
 
TXT OND Expands Regulatory Science Research
04/18/2023
 
 
TXT Intarcia Raises NDA Advisory Committee Issues
04/18/2023
 
 
TXT House Oversight Panel Puts Heat on FDA Over CBD
04/18/2023
 
 
TXT Research Describes Drug Ad Data Display
04/18/2023
 
 
TXT Royal Chemical Inspection Finds CGMP Violations
04/18/2023
 
 
TXT Multiple Abbott i-STAT Test Violations
04/18/2023
 
 
TXT Workshop on Rare Disease Endoints
04/17/2023
 
 
TXT Panel Backs Rexulti for Alzheimer’s Agitation
04/17/2023
 
 
TXT FDA Clears Reader for FreeStyle Libre 3
04/17/2023
 
 
TXT Avenue Therapeutics Plans IV Tramadol Resubmission
04/17/2023
 
 
TXT GSK Plans NDA for Antibiotic Gepotidacin
04/17/2023
 
 
TXT FDA ‘Top Cop’ McMeekin Retiring 6/30, Then Many More
04/17/2023
 
 
TXT Gamida Cell Therapy Approved by FDA
04/17/2023
 
 
TXT Complete Response on Lilly’s Ulcerative Colitis Drug
04/14/2023
 
 
TXT High Court Issues 5-day Stay in Abortion Drug Case
04/14/2023
 
 
TXT GOP Reps Challenge Generics from ‘Alert’ Firms
04/14/2023
 
 
TXT 2nd Complete Response on Alvotech Humira Biosimilar
04/14/2023
 
 
TXT FDA Wants 2nd Study in Solgenix NDA
04/14/2023
 
 
TXT Moximed Knee Shock Absorber Cleared
04/14/2023
 
 
TXT Lupin Hit with 13-page 483 at India Plant
04/14/2023
 
 
TXT PTA, Specialty Catheter Submission Guidance
04/13/2023
 
 
TXT FDA ‘Rewrites’ History, Facts in Coreg Label Case: GSK
04/13/2023
 
 
TXT FDA Accepts De Novo AlgoDx Sepis Detector
04/13/2023
 
 
TXT FDA Clarifies Philips BiPAP, CPAP Replacement Numbers
04/13/2023
 
 
TXT Government Turns to High Court in Mifepristone Appeal
04/13/2023
 
 
TXT Guide on OTC Monograph Order Requests
04/13/2023
 
 
TXT Panels to Consider Rexulti sNDA for Alzheimer’s Agitation
04/13/2023
 
 
TXT Texas House Approves Drug Import Bill
04/13/2023
 
 
TXT Pilot Program on Radiation Sterilization Master Files
04/12/2023
 
 
TXT Format/Content of OTC Monograph Order Request
04/12/2023
 
 
TXT Assessing Adhesion with Transdermal Systems
04/12/2023
 
 
TXT Pragmatica-Lung Study Launches
04/12/2023
 
 
TXT Omega Packaging CGMP Violations
04/12/2023
 
 
TXT Class 3 Device Changes Up Recall Risk: Study
04/12/2023
 
 
TXT Vanda Wants Teva Generic Hetlioz Pulled
04/12/2023
 
 
TXT Transdermal Irritation/Sensitization Assessment
04/12/2023
 
 
TXT Both Sides Argue Over Jurisdiction in Abortion Case
04/12/2023
 
 
TXT Safety Alert on O&M N95 Respirators
04/12/2023
 
 
TXT Clinical Trial Monitoring Q & A Guide
04/11/2023
 
 
TXT Partial Hold on Molecular Templates Study
04/11/2023
 
 
<< Prev  11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30  Next >>
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving